ArticleThe oncologist2025
Clinical utility of companion diagnostic biomarker results below the limit of detection in comprehensive genomic profiling of patients with advanced non-small cell lung cancer.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhen the limit of blank (LoB) of comprehensive genomic profiling (CGP) for a given biomarker is acceptably demonstrated (ie, α ≤ 0.05 or LoB equal to zero), biomarkers detected below the assay limit of detection (LoD) can be reported with a high degree of confidence. However, it is unknown whether variants detected below LoD have clinical utility. PATIENTS AND
methodsThis study used a de-identified nationwide (US-based) non-small cell lung cancer clinico-genomic database (CGDB) containing linked FDA-approved CGP testing from Foundation Medicine, Inc (FMI). We selected patients who received an FMI CGP report with an actionable biomarker detected below LoD. We assessed clinical utility among those patients who received an appropriately matched targeted therapy, defined as a real-world overall response rate exceeding a prespecified threshold of 30% based on historical chemotherapy response rates.
resultsAmong 129 patients who had a biomarker detected and reported below LoD, received the appropriate matched targeted therapy, and were assessed for response, partial or complete response was observed in 36/54 (67%, one-tailed 95% CI: >55%, P < .001) patients tested with a tissue-based CGP test and 54/75 (72%, one-tailed 95% CI: >62%, P < .001) patients tested with a liquid-based CGP test, both of which exceeded the prespecified threshold for clinical utility.
conclusionsMost patients who receive a targeted therapy matched to a companion diagnostic biomarker detected and reported below LoD demonstrate clinical benefit from that therapy. This clinical observation suggests actionable variants should continue to be reported when detected with FMI CGP tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.